


# Infusion reactions curriculum



Anastasiya (Stacy) Bagrova MD, Lena Eder MD, Elizabeth Hankollari MD, Lisa Criscione-Schreiber MD




# Objectives

- Distinguish between four types of hypersensitivity reactions
- Be able to recognize symptoms and signs of mild, moderate, and severe reactions
- Recognize basic management principles for drug sensitivity reactions

## Why is this important?

- Infusion therapies are becoming standard in many fields
- High rate of infusion reactions:
  - Rituximab – 27% of RA with first infusion; <1% severe
  - Infliximab – 20% with first infusion; <3% severe
  - Tocilizumab – 8% with first infusion; 0.2% severe



# Hypersensitivity Reaction Types

Type	Immune response	Pathophysiology	Clinical symptoms	Timing
1	IgE	Mast cell and basophil degranulation	Anaphylactic shock Angioedema Urticaria Bronchospasm	1-6 hours
2	IgG and complement (C')	IgG and C'-dependent cytotoxicity	Cytopenia	5-15 days
3	IgM or IgG and complement	Immune complex deposition	Serum sickness Urticaria Vasculitis	7-21 days
4	Cell mediated immunity	Monocytic, eosinophilic, or neutrophilic inflammation Keratinocyte death mediated by CD4/8	Eczema DRESS, maculopapular rash AGEP  SJS/TEN	Days to weeks

# Immediate Hypersensitivity Reactions

<b>Mechanism</b>	<b>Timeline</b>	<b>Clinical Features</b>
IgE-mediated	Usually after uneventful prior exposure	Urticaria, atopy, anaphylaxis
IgG-mediated	Onset usually after several exposures	Bloating, nausea, headaches
Cytokine release syndrome (anaphylactoid, non-IgE mediated)	Onset varies; immediate to prolonged	Fever and chills

# Clinical presentation by severity

## Mild


- Limited to one organ system and mild

## Moderate

- At least 2 organ systems but hemodynamically normal

## Severe

- At least 2 organs systems + hypotension, and/or hypoxia (<92%)



HR



BP

# Management by severity



Mild (grade 1)

Continue infusion



Moderate (grade 2)

Decrease rate by 50%/ hold  
and restart at lower rate

Anti-histamines,  
acetaminophen



Severe (grade 3-4)

Stop infusion

Anaphylaxis algorithm

Activate emergency  
response

ABC

- IM Epinephrine (1mg/ml) – 0.3-0.5 IM q5-15 min

ABC (cont.)

- Recumbent position
- Give oxygen
- Give IV fluids
- Albuterol PRN for bronchospasm

Adjuncts

- Diphenhydramine 25-50 mg IV, H2-blocker (urticaria, itching)
- Methylprednisolone 125 mg IV
- Telemetry monitoring, continuous pulse ox

Refractory symptoms

- Epinephrine drip- 0.1mcg/kg/min
- Glucagon – BB may prevent response to epinephrine – 1-5 mg IV over 5 min, then 5-15 mcg/min infusion → can cause vomiting





# Take Home Points

- Infusion therapies are becoming more and more common and it is important to recognize their severity and know how to manage them
- Anaphylaxis occurs when 2 or more system are involved; anaphylactic shock is associated with hemodynamic instability
- IM epinephrine is key in management and there are NO contraindications
- Fluids, anti-histamines, steroids, and H2-blockers come after epinephrine for supportive care

# References

Simons, F. E. R., Ebisawa, M., Sanchez-Borges, M., Thong, B. Y., Worm, M., Tanno, L. K., ... & Sheikh, A. (2015). 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. *World Allergy Organization Journal*, 8(1), 1

Vogel WH. Infusion reactions: diagnosis, assessment, and management. *Clin J Oncol Nurs* 2010; **14**: E10– 21

Buelow, B. Immediate Hypersensitivity Reactions. *Medscape. Drug and Disease. Allergy and immunology*. 2015 <https://emedicine.medscape.com/article/136217-overview#a5>

Murphy, Ken, and Casey Weaver. *Janeway's immunobiology*. Garland Science, 2016.

Demoly, Pascal, et al. "International Consensus on drug allergy." *Allergy* 69.4 (2014): 420-437

Type II Hypersensitivity. *Pathway Medicine. Immunology. Immune Pathology. Hypersensitivity Reactions*. 2010-2017. <http://pathwaymedicine.org/type-ii-hypersensitivity>

# Acknowledgments

- Study PIs: Dr. Lisa Criscione-Schreiber and Dr. Elizabeth Hankollari
- Duke Learning and Development Center: Dr. Sophia Stone, Stephen Toback, Devon Henry